Great Science
Deep Compassion
Real Impact
Leveraging our long-standing neuroscience
expertise to develop medicines that
make a difference.
Featured News
July 21, 2025
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
June 02, 2025
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
Made in Ohio
Our Wilmington, Ohio manufacturing facility is central to our ability to deliver FDA-approved medicines for people living with serious diseases. Learn about the work done at this state-of-the-art facility, operated by dedicated people who are deeply connected to the local community.
Understanding Narcolepsy
Narcolepsy is a rare neurological disorder that is often misunderstood and stigmatized. Our team members describe the physical symptoms that people living with this sleep disorder face, along with the emotional and psychological impact, in a video created to foster understanding.
Notable Recognition
We are honored to be recognized as an employer of choice in the life sciences industry. Visit our Awards & Recognition page to see the latest accolades bestowed on Alkermes by leading news and ranking organizations.
R&D Pipeline
We apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We are currently focused on developing these investigational candidates.
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
-
Olanzapine and samidorphan
-
Schizophrenia and Bipolar I Disorder (Pediatric)
Phase 3
OverviewOlanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.
Clinical TrialsOlanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
-
-
Alixorexton
-
Narcolepsy Type 1
Phase 2
-
Narcolepsy Type 2
Phase 2
-
Idiopathic Hypersomnia
Phase 2
OverviewAlixorexton (formerly ALKS 2680) is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.
Clinical TrialsAlixorexton is currently being evaluated in a global phase 2 program. Vibrance-1, a phase 2 study in adults with narcolepsy type 1, has completed enrollment. Vibrance-2, a phase 2 study in adults with narcolepsy type 2, and Vibrance-3, a phase 2 study in adults with idiopathic hypersomnia are ongoing. Participants who complete one of the Vibrance studies have the option to continue in a long-term, open-label, safety study evaluating the safety of alixorexton for up to two years.
For more information about these studies, please visit vibrancestudies.com (for U.S. audiences only) or the respective clinicaltrials.gov listings:- Vibrance-1: clinicaltrials.gov/study/NCT06358950
- Vibrance-2: clinicaltrials.gov/study/NCT06555783
- Vibrance-3: clinicaltrials.gov/study/NCT06843590
-
-
ALKS 4510
-
Neuroscience Indications
Phase 1
OverviewALKS 4510 is an investigational orexin 2 receptor agonist in developement for the treatment of central nervous system disorders. It is currently being evaluted in a phase 1 study in healthy volunteers.
-
-
ALKS 7290
-
Neuroscience Indications
Preclinical
OverviewALKS 7290 is an investigational orexin 2 receptor agonist being evaluated preclinically for the treatment of central nervous system disorders.
-
